FR2235678A1 - Topical antipsoriasis agents - contg. prostaglandin E1 or E2 - Google Patents

Topical antipsoriasis agents - contg. prostaglandin E1 or E2

Info

Publication number
FR2235678A1
FR2235678A1 FR7422648A FR7422648A FR2235678A1 FR 2235678 A1 FR2235678 A1 FR 2235678A1 FR 7422648 A FR7422648 A FR 7422648A FR 7422648 A FR7422648 A FR 7422648A FR 2235678 A1 FR2235678 A1 FR 2235678A1
Authority
FR
France
Prior art keywords
pge1
prostaglandin
pge2
pref
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7422648A
Other languages
French (fr)
Other versions
FR2235678B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of FR2235678A1 publication Critical patent/FR2235678A1/en
Application granted granted Critical
Publication of FR2235678B1 publication Critical patent/FR2235678B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Medicaments for topical application for the treatment of psoriasis consist of an inert pharmaceutical carrier contg. an effective amount of prostaglandin E1 (PGE1) or prostaglandin E2, opt. together with a phosphodiesterase inhibitor (pref. theophylline, papaverin e or 5-chloro-6-ethylamino-1,3-dihydro-2H-imidazo 4,5-b pyrazin-2-one)- . Pref. medicaments contain 0.05-5 wt % PGE1 or PGE2 and 0.05-5 wt % phosphodiesterase inhibitor. The medicaments are pref. administered topically or by injection into the affected areas. Topical formulations include aerosol sprays, powder sprays, isotonic aqs. solns. lotions, creams, ointments, and solid salve sticks. The specification includes results of in vitro tests showing that PGE1 or PGE2 or their combinations with theophylline increase the concentration of cyclic AMP in normal human skin, psoriatic plaques, and 'normal adjoining' skin tissue. Present knowledge of the relationship between skin cyclic AMP concentrations and psoriasis indicates that PGE1 or PGE2, opt. together with a phosphodiesterase inhibitor, constitutes an effective treatment of psoriasis.
FR7422648A 1973-07-02 1974-06-28 Topical antipsoriasis agents - contg. prostaglandin E1 or E2 Granted FR2235678A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37558873A 1973-07-02 1973-07-02

Publications (2)

Publication Number Publication Date
FR2235678A1 true FR2235678A1 (en) 1975-01-31
FR2235678B1 FR2235678B1 (en) 1977-11-04

Family

ID=23481471

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7422648A Granted FR2235678A1 (en) 1973-07-02 1974-06-28 Topical antipsoriasis agents - contg. prostaglandin E1 or E2

Country Status (2)

Country Link
DE (1) DE2431558A1 (en)
FR (1) FR2235678A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390964A1 (en) * 1977-05-20 1978-12-15 Wellcome Found DRUG ASSOCIATIONS INCLUDING PROSTACYCLINE OR DIHYDROPROSTACYCLINE
EP0015658A1 (en) * 1979-02-12 1980-09-17 American Cyanamid Company Topical compositions containing prostaglandine derivatives
EP0195496A2 (en) * 1985-01-21 1986-09-24 Beecham Group Plc Use of xanthines in the treatment of proliferative skin disease
EP0552439A1 (en) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Pharmaceutical preparations for topical use in the treatment of psoriasis and atopical dermatitis
US5905091A (en) * 1996-07-03 1999-05-18 The Board Of Regents Of The University Of Oklahoma Enhancement of skin pigmentation by prostaglandins
CN113226304A (en) * 2018-12-29 2021-08-06 上海明隽生物技术有限公司 Immunosuppressive pharmaceutical composition and application thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337254A (en) 1977-08-23 1982-06-29 Burroughs Wellcome Co. Pharmaceutical compositions
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEANT *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390964A1 (en) * 1977-05-20 1978-12-15 Wellcome Found DRUG ASSOCIATIONS INCLUDING PROSTACYCLINE OR DIHYDROPROSTACYCLINE
EP0015658A1 (en) * 1979-02-12 1980-09-17 American Cyanamid Company Topical compositions containing prostaglandine derivatives
EP0195496A2 (en) * 1985-01-21 1986-09-24 Beecham Group Plc Use of xanthines in the treatment of proliferative skin disease
EP0195496A3 (en) * 1985-01-21 1990-01-17 Beecham Group Plc Use of xanthines in the treatment of proliferative skin disease
EP0552439A1 (en) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Pharmaceutical preparations for topical use in the treatment of psoriasis and atopical dermatitis
US5905091A (en) * 1996-07-03 1999-05-18 The Board Of Regents Of The University Of Oklahoma Enhancement of skin pigmentation by prostaglandins
CN113226304A (en) * 2018-12-29 2021-08-06 上海明隽生物技术有限公司 Immunosuppressive pharmaceutical composition and application thereof

Also Published As

Publication number Publication date
DE2431558A1 (en) 1975-01-23
FR2235678B1 (en) 1977-11-04

Similar Documents

Publication Publication Date Title
EP0206291A3 (en) Sprayable pharmaceutical preparation for topical application
SE8001599L (en) TRANSDERMAL MEDICATION SYSTEM FOR ISOSORBID DINITRATE
EP0336880A3 (en) Use of topical applicable preparation for treating skin aging
NO944957L (en) Galenic composition, method of preparation thereof, and use thereof
GB1001949A (en) Penetrating agents
KR900017590A (en) Acne treatment method and pharmaceutical composition thereof
ES2061989T3 (en) USE OF ALKYL ESTERS OF PYROGLUTAMIC ACID FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ICTIOSIS.
FR2235678A1 (en) Topical antipsoriasis agents - contg. prostaglandin E1 or E2
US4039664A (en) Topical griseofulvin composition and method
ES2038359T3 (en) PROCEDURE FOR OBTAINING INTRAMUSCULAR INJECTION FORMULATIONS FROM GIRASE INHIBITORS.
US3957994A (en) Topical anti-inflammatory composition and method of use
KR910005858A (en) Fatty acid therapy
JPS5699412A (en) Rosemary aciddcontaining pharmaceutic product
HK1001323A1 (en) Anti-irritant and desensitizing compositions and methods of their use
GB1218125A (en) Composition for treating acne
US3777020A (en) Psoriasis treatment with mycophenolic acid
KR910021238A (en) Keloid Remedy
IE810891L (en) Topical formulation
ES2031462T3 (en) PROCEDURE TO PRODUCE 1-B-D-ARABINOFURANOSILCITOSINA-5'-STERARILFOSFATO MONOSODICO AND MONOHIDRATO OF THE SAME, AND PHARMACEUTICAL COMPOUND THAT CONTAINS THIS LAST.
CH421946A (en) Process for the preparation of ascorbic acid diesters
EP0023355A3 (en) Medicinal solutions and process for their preparation
EP0009793A3 (en) Pharmaceutical composition containing a derivative of 2-(retinylidene)-malonic acid, manufacturing process and application
DE3579074D1 (en) REDUCTION OF THE TOXIC EFFECTS OF ANTHRACHINONE DRUGS.
FR2598M (en) New derivatives of anthrauilic acid, usable in therapy, in particular as anti-inflammatory agents.
GB1215152A (en) Biguanide derivatives and pharmaceutical preparations containing them

Legal Events

Date Code Title Description
ST Notification of lapse